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Abstract
Background – The number of bacterial strains
resistant to antibiotics is growing exponentially.
Antibiotics are often prescribed more than needed due
to the delay period in diagnosing the pathogen and
giving treatment. This delay often pushes prescribers
to give a broad-spectrum antibiotic or pushes them to
make the patient wait for the proper treatment, in turn
allowing the bacterium to potentially mutate. This
creates a need for a more rapid, easily used, and cost
effective method of identifying pathogens. The
objective of this study is to validate the CAPTURE™
method and its ability to identify pathogens, reduce the
mechanical processing time, and optimize the sample
preparation and lysis protocols.
Methods – The methods for this project included
several steps: captor design, sample acquisition,
sample prep, sample testing using the CAPTURE™
method, assay analysis, sample comparison, and
optimization. Urine samples were gathered from
patients with suspected urinary tract infections at the
University of Alabama in Huntsville’s Faculty & Staff
Clinic. Each patient consented to give two urine
samples, one sample was sent to the facility’s
contracted lab for routine identification. The second
sample was sent to GeneCapture and considered
discarded and de-identified. Institutional Review

Board approval was received and is on file from the
University of Alabama in Huntsville.
Results – To determine the accuracy of the
CAPTURE™ assay pathogen identification, the
results from the contracted lab were compared to the
results of the CAPTURE™ assay. The results showed
that the CAPTURE™ method has the ability to
identify pathogens from the lysates.

I. Introduction
The purpose of this research study is to test
the validity and reliability of the CAPTURE™
method. The CAPTURE™ was created by
GeneCapture, Inc., a start-up company in the
Biotechnology field. The CAPTURE™ (Confirming
Active Pathogens Through Unamplified RNA
Expression) method uses a molecular diagnostic
technique to determine a genetic match for the
pathogen using DNA captors that will identify the
pathogen in less than one hour for minimal cost.
CAPTURE™’s purpose is to rapidly diagnose
bacterial and viral pathogens. The need for a more
rapid diagnostic testing method continues to grow
exponentially as antibiotic resistance increases, strains
mutate, and cost of healthcare rises.
To begin the study, a partnership was
cultivated between GeneCapture, Inc. and the
University of Alabama in Huntsville’s Faculty & Staff
Clinic, a division of the College of Nursing.
Institutional Review Board approval was received
from The University of Alabama in Huntsville
(Appendix A). Patients that presented symptoms of a
urinary tract infection (the phrase urinary tract
infection will be further noted as UTI in this text) were
recruited to participate in the study and consented to
give two urine samples (Appendix B, 1) (Appendix B,
2), one to be run through the CAPTURE™ method and
the other sent for a culture and sensitivity to the
contracted laboratory for usual diagnostic tests and
treatment.
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The anticipated outcome of this research is
the verification of CAPTURE™, through comparative
results, to correctly identify these common urinary
tract pathogens. These findings may advance further
into other infectious pathogens and may be useful in
correctly and rapidly diagnosing common to serious
infections in clinics and areas with no access to
laboratory facilities.

II. Background
PCR
Polymerase chain reaction (denoted as PCR
through the rest of the text) is a technique used in many
laboratories and development companies worldwide.
This technique was invented in the 1980s and has been
making many advances in recent decades. PCR allows
a particular DNA region, selected by the researcher, to
be targeted and copied (“Polymerase Chain Reaction”,
2017). Generally, a researcher would want multiple
copies of a specific region to analyze it for certain
characteristics or functions or pathogen identification
(Järvinen, 2009).
For PCR to function, a DNA polymerase
enzyme is required to make new strands of DNA. Taq
polymerase is the most common DNA polymerase
used for PCR. This particular polymerase is derived
from a heat-tolerant bacterium, making it ideal in
PCR. PCR uses high temperatures at many points in
the process to denature the template DNA
(“Polymerase Chain Reaction”, 2017). For the
polymerase to work, a primer is needed. Two primers
are used in a PCR experiment; these primers are short
pieces of single-stranded DNA. Each primer is tasked
with surrounding the target region of DNA and
binding to opposite strands of the template DNA,
leaving the target region unbound (“Polymerase Chain
Reaction”, 2014). When the strands are cooled, the
primers are allowed to bind to the template. Once they
are bound, the temperature is increased allowing
synthesis of new DNA.
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This process occurs 25-35 times in a single
PCR experiment. Each experiment takes between two
and five hours. The time will depend on the length of
the DNA sequence that is targeted and being copied.
(“Polymerase Chain Reaction”, 2014) After the
reaction is complete, gel electrophoresis is often used
to visualize the reaction. This process takes between 1
and (Järvinen, 2009) 1.5 hours (“Agarose Gel
Electrophoresis”, n.d.). PCR can also be analyzed on a
microarray (Järvinen, 2009). Often, when analyzing a
PCR reaction, a researcher may find unexpected
amplifications. A limitation of PCR is its need for
sample purity. If a contaminant is involved in the
reaction, the contaminant may be copied as well,
skewing the results (Brookman-Amissah, 2014). Extra
steps to prevent contamination between samples must
be taken.
CAPTURE™
Confirming Active Pathogens Through
Unamplified RNA Expression (the phrase will be
further noted as CAPTURE™ in this text) is a method
developed by GeneCapture, Inc. to be used as a rapid
diagnostic tool. CAPTURE™ uses a stem-loop captor
to identify pathogens. The stem is a specific sequence
that does not change. The loop is a unique sequence
from the pathogen(s) that the specific panel is trying to
identify.
The CapLab is the machine, designed by
GeneCapture, to carry out the CAPTURE™ process.
A lysate from a sample (in this case from urine) was
placed in a cartridge along with buffers and targets.
The sample is run across an array of appropriate stemloop captors. If the sequence of the sample finds a
match in one of the loops, it will bind. Once the sample
binds, the loop is forced to open and an
oligonucleotide binds to the hanging stem. This oligo
acts as the detector, producing the signal needed to
analyze (Boeteng, 2013). (See Figure 1)
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Figure 1: Pathogenic nucleic acids pass over the
captors on the microarray and bind to their
complement in the loop region; this binding forces the
stem to open (the captors only remain open if the
correct target has bound). The captors that remain
open then bind to a universal detector. The microarray
is washed stringently to remove any mismatched or
unbound nucleotides (Koelle, 2014.)
After this process, the array is cooled back down to
allow the loops with no binding to close. The
microarray can then be analyzed for the specific
pathogen (Boeteng, 2013). (See Figure 2)

Figure 2: Microarray. Identifies which captors bound
to the sample. The fluorescent detector shows the
signal from each bound captor. The ‘landing lights’
allow the person analyzing to orient the direction of
the array and to correctly identify which captors
bound. (Koelle, 2014.)
CAPTURE™ looks at expressed RNA rather
than rDNA. It has the ability to target hundreds of
pathogens in a single assay (Pusey, Chittur, 2007).
Captors do have the potential to cross-react with other
species but statistical cluster analyses are completed to
counter this possibility. For more information
regarding the specific binding processes and
hybridization, refer to Novel stem-loop probe DNA
arrays: Detection of a specific acetotrophic 16s
ribosomal RNA signatures, 2012, Jonas Boateng,
Robert Zahorchak, Joel Peek, & Krishnan Chittur.

26

Perpetua Volume 2, Issue 1
PCR & CAPTURE™ Comparison

Disease Coverage
Specificity

Cost
Sample Turn-AroundTime
Primer Binding

PCR
CAPTURE™
Looks at one pathogen at a Targets hundreds of pathogens
time
in a single assay
Sample purity is key,
Crude lysates from any matrix
contaminates are often
(urine, blood, saliva)
amplified or duplicated
>$100/test
~$20/test
few hours to days
Currently 1 hour, goal <30
minutes
rDNA
Expressed RNA

In this table, the CAPTURE™ diagnostic is compared to multiplex PCR
UTIs
Many factors, lifestyles, and diagnoses such as
an active sexual life, menopause, diabetes, difficulty
emptying the bladder, or obstruction may lead to UTIs.
All of these factors influence the high occurrence rate
of UTIs, especially among women. Research has shown
that 40 to 60 percent of women will have at least one
urinary tract infection in their lives (Stapleton, 2017).
Male and female UTIs add up to approximately 150
million cases worldwide per year related with an
estimated $6 billion dollar healthcare expenditure
(Baldato, 2016). Due to the rate of occurrence, ease of
access, and the need for rapid identification, this study
chose to collect and analyze suspected UTI samples.
The current method for identifying pathogens
in human urine samples is a lengthy process, usually
taking two to three days to complete. First, a clean catch
midstream void is collected and then a dipstick
urinalysis is performed, ending with a quantitative urine
culture completed by a lab (Baldato, 2016). Due to this
delay in a specific diagnosis of the infecting pathogen,
a broad-spectrum antibiotic is often given (Zeeman,
2007). If the culture results differ from the original
speculation and the antibiotic given does not hinder the
pathogen identified as the infectant, the patient has
received an unnecessary treatment that could later lead
to antibiotic resistance (Ventola, 2017). Additionally, if
the pathogen is not identified rapidly, the pathogen has
the potential to mutate and move, causing acute
pyelonephritis (kidney infection) (“Urinary Tract
Infections”, 2017).
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Antibiotic Resistance
Antibiotic resistance is the innate or acquired
ability of bacteria to resist the effects of antimicrobial
agents. Acquired resistance is of more concern due to
the possibility of rendering currently effective drugs,
ineffective (Burchum, 2016). Over time, bacteria may
become less sensitive to an antibiotic or may lose all
sensitivity (Burchum, 2016). Antibiotic resistance is
increasing due to overuse and misuse of antibiotics
(“Get Smart”, 2014), extended hospitalization
(Burchum, 2016), and antibiotic use among food
sources i.e. giving animals antibiotics (“Get Smart”,
2014). Research studies have shown that 30 to 50
percent of antibiotics given were incorrect for the
infection or the duration of the treatment (Ventola,
2017).
Antibiotics are only effective against bacteria,
not viruses or fungi. These agents are not effective
against common colds, gastrointestinal viruses, the flu,
most sinus infections, or ear infections (“Get Smart”,
2014); however, they are often prescribed for these
diagnoses due to delayed diagnostic testing to identify
the specific infecting pathogen, patient knowledge
deficit, and improper provider prescriptions.

III. Methods
Captor Design
Captor design is crucial to the functionality of
the CAPTURE™ method. The purpose of the captor
design process is to identify a sequence unique to each
pathogen with little to no crossover with other species.
Some pathogens fall in the same phylum or genus but
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still need to be differentiated to come to a proper
diagnosis. There is still the potential of crossover
between species; therefore, statistical cluster analyses
were completed to account for the potential
interactions. GeneCapture owns a proprietary software
program that utilizes uploaded genomic information of
the most highly expressed genes to seek out sequences
that are common to an individual pathogen but also
retain unique areas that set it apart from other any
others. The sequences are then attached to the
‘universal stem’ and placed on the array. Though the
captor design process looks for a unique sequence for
each pathogen, it still must take into account the
constantly changing nucleic acids in each organism. For
this reason, multiple captors are designed for each
pathogen and placed on the array; up to 5 captors will
be used for one pathogen. Positive and negative
controls are included on each array.
Sample Acquisition
Samples were gathered from patients with
suspected UTIs that presented to the University of
Alabama in Huntsville’s Faculty & Staff Clinic. The
staff of the clinic asked the patients if they would give
two samples, one for regular lab testing and one to be
given to GeneCapture for testing. Patients were made
aware that none of their personal information would be
given to GeneCapture or be used for this study. The
samples were considered discarded and de-identified.
Samples were kept in a refrigerator at the clinic until
time of acquisition. The samples were then transported,
by a GeneCapture staff member, to the lab in a marked
biohazard container.
Sample Prep
To prepare each sample received from the
clinic, a specific series of manual steps were followed.
In this process a lysis buffer was used to break open the
cells of the pathogen and fragment the RNA. (The
specific process and lysis buffer have been excluded
from this text for proprietary reasons). After the steps
were completed, a sample of the lysate was plated to
confirm sterility. In addition, through dilution plating, a
portion of each original urine sample was used to
confirm and compare growth and identity of the
pathogen with the results received from the clinic’s
contracted laboratory.
Sample Testing
The lysate along with the buffers (the specific
buffers have been excluded from this text for
proprietary reasons) are paced in a cartridge designed
specifically for the CapLab. The machine uses a simple
pump, like that used in a common aquarium, to move a

succession of fluids (the lysate and buffers) across the
array. As the fluid moves across the array, the target
(lysate) binds to the corresponding captors. A rinse is
then completed to wash away any excess target. The
fluorescent detector will then bind to the open captors
and another rinse will be completed. A final rinse is
completed to stabilize duplex formation before
scanning.
Assay Analysis
The future of the CapLab will allow the assay
analysis and, therefore the identification of the
pathogen, to be completed within the CapLab itself.
(See Figure 3).

Figure 3: Vision for future CapLab design.
During this study a GenePix 4200b Scanner
(Molecular Devices, Inc, Sunnyvale, CA) was used to
scan the resulting microarrays containing the now
closed captors and bound florescence. (See Figure 2).
With the map of the placement of each captor, the
pathogen was identified from the signal on the array.
Comparison
Once the assay was analyzed and the infecting
pathogen determined by the CAPTURE™ method, the
results were compared to the results given by the
University’s contracted lab. The results from the lab
took 2-3 days to receive.
Optimization
After each sample was tested and analyzed, the
process was scrutinized for areas that needed
improvement due to overlap, lack of specificity, and
chemical change. During the time that this particular
study was completed, the lysis protocol was updated
several times and captors were redesigned.
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IV. Results
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Shown above, the results from the contracted
lab are compared to the results of the CAPTURE™
assay. When a negative result was received from the
CapLab and not the laboratory, the captors as well as
the lysis protocol were analyzed for areas that needed
optimization. Some captors had to be redesigned to
have a higher specificity and less overlap with other
species. The lysis protocol had to be adjusted to account
for samples that yielded very small amounts of lysate.
The CAPTURE™ results for sample UAH002
did not yield E.coli as the culture results did. It was
determined that the RNA extraction process for this
sample resulted in too little detectable RNA. E. coli was
detected in future samples. Culture results for the
samples UAH001 and UAH011 found Streptococcus
agalactiae or Group B Strep. Further research showed
that this particular bacterium can be a cause of UTIs, a
result of a kidney stone and can be very harmful during
pregnancy. No captors for this bacterium were on the
panel used in this study; after discussion, captors for
this bacterium were designed and added to a new panel
for future studies.
A lab culture of “mixed flora” indicates that
only low levels of multiple bacteria were grown but
were not an indicator of infection. The mixed flora
result was most likely yielded due to a non-sterile urine
sample. The urinary tract and urine are sterile unless
contaminated by pathogens. Normal flora are bacteria
that live on or in a human body at all times. These
bacteria are not pathogenic and aid the body in fighting
off harmful bacteria. Every person carries normal flora
in areas such as the gastrointestinal tract, nose, mouth,
skin, and specifically, around the genitals. Using a clean
catch method to obtain a urine sample would eliminate
this flora from contaminating a sample; however,
patients often complete the clean catch method
incorrectly, resulting in a contaminated sample. (See
figure 4 for steps to gather a proper clean catch sample)

V. Conclusion
This study, which specifically looked at UTI
samples to validate and optimize the CAPTURE™
method is an ongoing study and is now being conducted
alongside other more in- depth studies at the
GeneCapture lab. Through this research study, it was
determined that the CAPTURE™ method does have the
ability to identify specific pathogens from human
samples. It was determined that the CAPTURE™
method can be completed in one hour with the direction
of being completed in less time as more steps in the

Figure 4: Steps to properly gather a clean
catch urine sample.
process become a part of the automation of the CapLab.
Further optimization of the UTI captor panel is
currently underway.
The CAPTURE™ method and this study have
many implications for medical and nursing practice.
This form of rapid diagnostics allows for determination
of the infecting pathogen in a clinic and at the bedside
for timely and accurate treatment, thereby reducing the
exponential growth in the number antibiotic resistant
pathogens. This technology has the potential and
accessibility to be used in areas with little to no access
to laboratories or medical facilities such as: military
camps, disaster areas, and wilderness/remote
installments. There are possibilities for use in pandemic
emergence and tracking. CAPTURE™ can also be
utilized in agriculture to identify plant pathogens
reducing crop destruction and increasing food
insecurity. There is also potential for cancer detection
and treatment monitoring. This research is ongoing and
it will be exciting to determine how this technology will
improve health outcomes, in the future.
Publication of the expanded validation study is
expected in the near future.
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